Medical Xpress November 2, 2025
Paul Sisson

Scripps Research in La Jolla announce a new clinical trial that will assess the effectiveness of using drugs approved for diabetes treatment and weight loss to treat long COVID-19, the debilitating chronic condition diagnosed in an estimated 20 million Americans and about 400 million people worldwide.

Developed to help people with type 2 diabetes control their blood sugar levels, these GLP-1 medications have generated billions of dollars in revenue for their ability to slow the pace of digestion and reduce appetite, helping millions worldwide lose weight.

But, as always happens with big pharma blockbusters, the is busy exploring other possible applications for this class of compounds, with underway or forming in cardiovascular disease, chronic kidney disease...

Today's Sponsors

Venturous
ZeOmega

Today's Sponsor

Venturous

 
Topics: Biotechnology, Healthcare System, Patient / Consumer, Pharma / Biotech, Provider, Public Health / COVID
What’s new with GLP-1s
Podcast: Medicaid vs. 340B: A Drug Pricing Clash (Sayeh Nikpay)
283: A candid conversation: Physicians on the front lines of GLP‑1 care
BigHat, Revvity Collaborate with Eli Lilly, Immunai Signs Agreement with Bristol Myers Squibb, SandboxAQ Launches New AI Model
Medicare Is Covering GLP-1s – It’s Time to Cover the Care That Makes Them Sustainable

Share Article